Clover Health’s (NASDAQ:CLOV) Q2 CY2026 Sales Top Estimates, Stock Jumps 10.3%
Clover Health (NASDAQ: CLOV) reported Q2 CY2026 revenue of $743.2 million, up 55.6% year over year, topping Wall Street estimates by about 2%. Full-year revenue guidance was $2.96 billion at the midpoint, about 1.7% above consensus. GAAP EPS was $0.05, $0.02 above estimates. Shares rose 10.3% to $4.58.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat expectations on revenue and GAAP EPS, and full-year revenue guidance at the midpoint came in above estimates. The reported immediate stock jump indicates the market is rewarding the combination of growth and profitability progress, but the company’s full-year earnings are still expected to be negative before flipping positive later.
Market read
This is a company-specific earnings and guidance beat that can drive near-term re-pricing, especially given the magnitude of YoY sales growth and the margin improvement cited.
What to watch
Adjusted operating margin is improving, but the article highlights a historically negative margin profile, so traders should watch whether the 5% adjusted operating margin profit is durable into subsequent quarters.
Background
Clover Health is a Medicare Advantage insurer using its Clover Assistant software, and the article frames the quarter as evidence of growth with improving profitability.
Ticker impact
Clover Health reported Q2 CY2026 revenue of $743.2M, up 55.6% YoY, and beat GAAP EPS and full-year revenue guidance at the midpoint.
Bullish bias for the next few sessions as traders digest the beat and guidance, with volatility likely given still-negative full-year earnings.
The article provides concrete Q2 results (revenue, GAAP EPS) and full-year revenue guidance versus estimates, which are direct drivers of re-rating. However, it also notes full-year earnings remain negative, limiting conviction on sustained upside without further margin/EPS inflection.
Market effects
Supports the narrative that Medicare Advantage insurers can grow while improving profitability, potentially lifting sentiment toward profitable MA peers.
Limited, primarily US healthcare/managed care sentiment.
Low, as the disclosure is company-specific and not a global macro driver.
Counterpoint
The stock reaction may fade if the market focuses on the still-negative full-year earnings outlook and the sustainability of margin gains.
Key entities
- companyClover Health
NASDAQ-listed Medicare Advantage insurer reporting Q2 CY2026 sales, GAAP EPS, and full-year revenue guidance.
- personAndrew Toy
CEO quoted on the company’s wide-network, full-risk Medicare Advantage model delivering outcomes and profitability.
